Invitae Corporation

Equities

NVTA.Q

US46185L1035

Biotechnology & Medical Research

End-of-day quote OTC Markets Other stock markets 18:00:00 2024-07-16 EDT			5-day change	1st Jan Change
0.0004 ^USD	+33.33%		-66.67%	-99.94%

06-13	First Amended Disclosure Statement Approved for Invitae Corporation	CI
06-11	Motion for Exclusivity Period Extension Approved For Invitae Corporation	CI

Invitae Corporation Reports Unaudited Revenue Results for the Year 2021

January 10, 2022 at 06:59 am

Invitae Corporation reported unaudited revenue results for the year 2021. The company generated revenue of more than $458 million in 2021, an approximate 64% increase from $279.6 million in 2020. Generated billable volume of more than 1.16 million in 2021, an approximate 76% increase from billable volume of 659,000 in 2020.

Latest news about Invitae Corporation

First Amended Disclosure Statement Approved for Invitae Corporation	06-13	CI
Motion for Exclusivity Period Extension Approved For Invitae Corporation	06-11	CI
First Amended Joint Liquidation Plan and Disclosure Statement Filed by Invitae Corporation	06-11	CI
North American Morning Briefing : PCE Inflation -2-	05-28	DJ
First Motion for Exclusivity Period Extension Filed by Invitae Corporation	05-21	CI
Joint Liquidation Plan and Disclosure Statement Filed by Invitae Corporation	05-09	CI
Motion for Asset Sale Approved for Invitae Corporation	05-07	CI
Labcorp beats quarterly estimates on strong testing demand	04-25	RE
Clinical lab operator Labcorp to buy bankrupt genetic test maker Invitae for $239 mln	04-24	RE
Laboratory Corporation of America Holdings (NYSE:LH) won the bid to acquire substantially all of the assets of Invitae Corporation for approximately $240 million.	04-23	CI
Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Substantially all Assets of Invitae Corporation (OTCPK:NVTA.Q).	04-23	CI
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance	04-11	CI
Invitae Launches Update to Invitae Generation: Clinical Variant Modeling Improves Variant Classification	03-12	CI
Earnings Flash (NVTA) INVITAE CORPORATION Posts Q4 Revenue $127.8M	03-06	MT
Invitae Corporation Provides Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2023	03-06	CI
Bidding Procedure Approved for Invitae Corporation	02-15	CI
Motion for Joint Administration Approved for Invitae Corporation	02-15	CI
Invitae gets court approval for five-month bankruptcy sale	02-15	RE
Global markets live: Airbnb, Sony, Uber, Lyft, Nvidia...	02-14
Genetic test maker Invitae files for bankruptcy protection in US	02-13	RE
Motion for Asset Sale Filed by Invitae Corporation	02-13	CI
Invitae Corporation Lists Estimated Assets In The Range Of $500 Mln -$1 Bln - Court Filing	02-13	RE
INVITAE CORPORATION LISTS ESTIMATED LIABILITIES IN THE RANGE OF…	02-13	RE
Genetic test maker Invitae files for voluntary Chapter 11 protection	02-13	RE
Motion for Joint Administration Filed by Invitae Corporation	02-12	CI

Chart Invitae Corporation

Duration

Period

More charts

Company Profile

Invitae Corporation is a medical genetics company. The Company is engaged in delivering genetic testing services, digital health solutions, and health data services that support a lifetime of patient care and improved outcomes. It offers genetic testing across multiple clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases and pharmacogenomics. It applies proprietary design, process automation, robotics and bioinformatics software solutions to expand the use and impact of genetic information in sample processing and complex variant interpretation, allowing medical interpretation at scale. The Company also utilizes digital health solutions to improve ease-of-use and to deliver actionable information about risk, prevention, treatment, and monitoring. The Company has served over 3.6 million patients, and over 2.2 million of those patients have made their information available for data sharing.

Sector

Biotechnology & Medical Research

Calendar

2024-08-05 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
INVITAE CORPORATION	-99.94%	85.95K
EXACT SCIENCES CORPORATION	-33.27%	9.17B
GUARDANT HEALTH, INC.	+20.33%	4.14B
IOVANCE BIOTHERAPEUTICS, INC.	+9.96%	2.63B
VERACYTE, INC.	-8.11%	1.95B
BGI GENOMICS CO., LTD.	-26.17%	1.85B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+41.83%	1.22B
CAREDX, INC	+52.50%	969M
SEEGENE, INC.	-6.77%	694M
CURIOX BIOSYSTEMS CO., LTD	-18.99%	235M

Bio Diagnostics & Testing